Mar. 1, 2016
The US-based Microbion Corporation announced on March 1, 2016 that it has entered into an agreement with China-based Haisco Pharmaceutical Group to develop and commercialize its lead clinical stage compound for wounds, MBN-101, in China and related territories. MBN-101 is the first in a new class of products to treat infections by attacking both bacteria and related biofilms. Haisco will be responsible for development, regulatory and commercialization costs for MBN-101 in China, and Microbion and Haisco will share profits from the commercialization of MBN-101 in China. Haisco is also making an equity investment in Microbion Corporation at the signing of the agreement.